Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Bristol-Myers

Takeda Pharmaceutical

Lawmakers have for years been concerned the U.S. is too reliant on foreign manufacturing of medicine.

Lawmakers pressure Big Pharma on drug supply chains amid coronavirus outbreak

AbbVie stock stumbled into a sell zone Wednesday as analysts expressed doubt the pharma company's early-stage pipeline could fill a Humira-size hole. Humira is facing rivals in Europe.

AbbVie Stock Snagged In Sell Zone As Humira-Size Hole Looms

AbbVie (ABBV) donates Kaletra/Aluvia to the government of China for experimental use in coronavirus treatment

AbbVie Backs Studies on HIV Drug Kaletra for Coronavirus Cure

The antiviral combination treatment Kaletra has reportedly shown promise against COVID-19 in China.

AbbVie to Test HIV Drug as a Potential Coronavirus Treatment

Allergan

AbbVie stock initially fell on its $63 billion plan to buy Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

AbbVie Is Nearing Its Massive Allergan Buyout — But Is ABBV Stock A Buy?

Agenus

Aphria

Atreca

Bicycle Therapeutics Plc - ADR

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals Inc

Amicus Therapeutics

GW Pharmaceuticals

OrganiGram Holdings Inc.

Pfizer

Arcus Biosciences

Sarepta Therapeutics

The coronavirus induced sell-off has created a number of attractive buying opportunities.

These 14 Stocks Are Stupid Cheap

Altria

PennyMac Mortgage Investment

AT&T

Exxon Mobil

These stocks remain positioned to maintain or increase their 5%-plus dividend yields. They could be good buys at current discounted prices.

5 High-Yield Dividend Stocks to Watch in the Coronavirus Sell-Off

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?

AbbVie (ABBV) Up 1.9% Since Last Earnings Report: Can It Continue?

Gilead Sciences

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Not yet, but multiple drugmakers are working on treatments and vaccines.

Is There a Cure for the SARS-CoV-2 Coronavirus?

AbbVie (ABBV) closed the most recent trading day at $90.64, moving -1.21% from the previous trading session.

AbbVie (ABBV) Stock Moves -1.21%: What You Should Know

Procter & Gamble

Dividend stocks are back as investors look for ways to ride out the volatility from the coronavirus outbreak. Here's three names to look at.

3 Dividend Stocks to Ride out the Market Volatility

Clorox

ProShares S&P 500 Dividend Aristocrats ETF

Plummeting stock prices have many traders concerned about a trend reversal. The dividend aristocrats suggest that a longer-term view may be needed.

Dividend Aristocrats Could Be Set to Lead Markets Higher

Aaron's

American Equity Investment Life

Broadcom

Citigroup

EOG Resources

Expedia

MSC Industrial Direct

Polaris

Unum

Westinghouse Air Brake Technologies

We're now officially in a correction with the S&P 500 down 12% in six consecutive days of losses.

11 Great Dividend Blue Chips To Profit From This Correction

AbbVie (ABBV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why You Shouldn't Bet Against AbbVie (ABBV) Stock

AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.

AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study

Veeva Systems

Coronavirus has many investors looking for a health stock bump, but these names are great for the long haul.

3 Top Healthcare  Stocks to Buy Right Now

There are a few potential backup plans. But all of them have drawbacks.

What Happens With AbbVie If Its Allergan Buyout Is Blocked?

Bausch Health Companies Inc

These three pharma stocks offer safe harbor in a volatile market.

3 Value Stocks to Buy if the Stock Market Implodes

Coca-Cola

Prologis

Royal Bank of Canada

W. R. Berkley

Daily Dividend Report: Royal Bank Of Canada, Coca-Cola, Prologis, W. R. Berkley, AbbVie

Franklin Resources

People's United Financial

The higher the market goes, the harder it becomes. The quest to find new or better equity investment ideas in a market where all-time highs are being pounded out routinely is becoming a challenge.

The 5 Highest-Yielding Dividend Aristocrat Stocks Have Solid Total Return Potential

The groups are worried about reduced competition if the merger goes through.

17 Consumer Groups and Unions Ask FTC to Block AbbVie's Acquisition of Allergan

A group of unions and consumer groups wrote to U.S. antitrust enforcers on Tuesday to oppose a proposed remedy that could lead to U.S.

Consumer groups, unions oppose fix for planned merger of AbbVie and Allergan

Eli Lilly

Which of these top dividend growth stocks is the more attractive buy right now?

Better Buy: AbbVie vs.  Eli Lilly

News for AbbVie Stock (ABBV)